KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Exchange Rate Effect (2021 - 2026)

Biocryst Pharmaceuticals filings provide 5 years of Exchange Rate Effect readings, the most recent being -$72000.0 for Q4 2025.

  • On a quarterly basis, Exchange Rate Effect rose 94.48% to -$72000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 235.68% increase, with the full-year FY2025 number at $1.3 million, up 235.68% from a year prior.
  • Exchange Rate Effect hit -$72000.0 in Q4 2025 for Biocryst Pharmaceuticals, up from -$468000.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $1.4 million in Q2 2025 to a low of -$1.3 million in Q4 2024.
  • Median Exchange Rate Effect over the past 5 years was $2000.0 (2021), compared with a mean of $70157.9.
  • Biggest five-year swings in Exchange Rate Effect: soared 16450.0% in 2022 and later crashed 349.81% in 2024.
  • Biocryst Pharmaceuticals' Exchange Rate Effect stood at $2000.0 in 2021, then soared by 16450.0% to $331000.0 in 2022, then skyrocketed by 57.7% to $522000.0 in 2023, then plummeted by 349.81% to -$1.3 million in 2024, then skyrocketed by 94.48% to -$72000.0 in 2025.
  • The last three reported values for Exchange Rate Effect were -$72000.0 (Q4 2025), -$468000.0 (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.